Skip to content
    Northpond Ventures logo

    Northpond Ventures

    Cambridge, Massachusetts, United StatesFounded 2018
    www.npv.vcLinkedIn
    Biotech & Life SciencesHealthcareAIFood & AgricultureClimate & Energy

    Northpond Ventures is a multi-billion-dollar science-driven venture capital firm that builds and supports breakthrough science and technology driven businesses to create a marked impact on humanity. The firm is an active lead life science investor with offices in Cambridge, MA; San Francisco, CA; and Bethesda, MD.

    41% of their portfolio is in Biotech & Life Sciences. Deal activity increased 400% year-over-year (5 deals in the last 12 months). Average disclosed round size is $54.8M (across 66 rounds with reported amounts).

    Find people at Northpond Ventures on Goldilocks AI

    Portfolio

    52

    Fund Size

    —

    Top Stage

    Series A

    Last 12 Mo

    5

    Team

    SK

    Sharon Kedar, CFA

    Co-Founder, Partner

    PM

    Paxton Major

    Managing Director

    AJ

    Andrea Jackson

    Partner

    PS

    Pat Smerkers, CPA

    Chief Financial Officer, Partner

    AJ

    Anjali Jagannath

    Vice President, Finance

    IL

    Ivan Learmont

    Vice President, Information Technology & Facilities

    LW

    Liz Wuestling

    Vice President, Business Analytics & Strategy

    TS

    Tim Schmidt, CPA, CFA

    Vice President, Fund Finance

    BH

    Ben Hartheimer

    Senior Associate, Portfolio Operations

    NF

    Nick Futrell

    Senior Associate

    SY

    Stephanie Yan

    Senior Associate

    SY

    Serena Yang

    Senior Analyst, Portfolio Operations

    Portfolio Breakdown

    Stage Distribution

    Sector Distribution

    Investment Activity

    DealsAvg Round Size

    Portfolio

    75 investments
    CompanyRoundAmountDate
    Mestag Therapeutics Limited logoMestag Therapeutics LimitedSeries B$40MMar 2026
    VieCure logoVieCureSeries A$43MJan 2026
    Vizgen logoVizgenSeries C$48MJan 2026
    Culture Biosciences logoCulture BiosciencesSeries C—Dec 2025
    Elephas Biosciences logoElephas BiosciencesSeries B$40MNov 2025
    GGaruda TherapeuticsSeries A$50MMar 2025
    Elephas Biosciences logoElephas BiosciencesSeries C$55MJan 2024
    Vigil Neuroscience logoVigil NeuroscienceSeries A$50MJan 2024
    VieCure logoVieCureUnknown$45MJan 2024
    Totus Medicines logoTotus MedicinesSeries B$66MDec 2023
    Aro Biotherapeutics logoAro BiotherapeuticsSeries B$41.5MNov 2023
    KKyverna TherapeuticsSeries B$60MAug 2023
    Vital Bio logoVital BioSeries A$18.6MJul 2023
    Vigil Neuroscience logoVigil NeuroscienceSeries B$90MJan 2023
    Sound Agriculture logoSound AgricultureSeries D$75MDec 2022
    Opna Bio logoOpna BioSeries A$38MNov 2022
    DDelfi Diagnostics, Inc.Series B—Jul 2022
    Delfi logoDelfiSeries B—Jul 2022
    Vizgen logoVizgenSeries C$85.2MJun 2022
    Sherlock Biosciences logoSherlock BiosciencesSeries B$80MMar 2022
    Opt Industries logoOpt IndustriesSeries A$15MMar 2022
    SSeLux Diagnostics, Inc.Series C$50MFeb 2022
    Story Health logoStory HealthSeries A$22.6MFeb 2022
    Kyverna logoKyvernaSeries B$85MJan 2022
    Ori Biotech logoOri BiotechSeries B$100MJan 2022
    Page 1 of 3

    Top Co-Investors

    ARCH Venture Partners9 shared
    Sands Capital8 shared
    OrbiMed7 shared
    Cowen Healthcare Investments7 shared
    Windham Capital Partners7 shared
    Rock Springs Capital7 shared
    Illumina Ventures6 shared
    Novalis LifeSciences6 shared
    Tao Capital Partners5 shared
    GV5 shared
    Menlo Ventures5 shared
    Foresite Capital5 shared
    Osage University Partners5 shared
    S324 shared
    Khosla Ventures4 shared
    Alexandria Venture Investments4 shared
    SV Health Investors4 shared
    Perceptive Advisors4 shared
    Cormorant Asset Management4 shared
    T. Rowe Price4 shared

    Last updated: 7 September 2026